Subscribe

TME Pharma N.V. (ALTME.PA)

EUR0.07 +0.00 (+1.65%)
DE PAR Healthcare Biotechnology
Address Max-Dohrn-Strasse 8-10 10589
Berlin, DE
CEO Diede van den Ouden
Website tmepharma.com
IPO 2016-09-30
ISIN NL0015000YE1

Explore sections of this company profile

Description

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR0.07 +0.00 (+1.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
236.4K
Beta
0.64
Float Shares
90.44M
Free Float %
96.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.50% +8.58% +11.82% +24.78% +28.89% +32.06% +3.49% -93.94% -99.79% -100.00% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.07
Ratings Trend (MoM) 100% Bullish
Rating 2025-04 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-145.27
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -100.0% Q4'25: -258.8% (vs Q4'23)
  • ✗
    EPS growth Biotechnology: +29.7%
    +83.4% ★ Q4'25: +97.3% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    — Q4'25: +2,063.0% (vs Q4'23)
  • ✗
    EBIT margin Biotechnology: +0.0%
    — Q4'25: +3,788.9% (vs Q4'23)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q4'25: +435.8% (vs Q4'23)
  • ✗
    Share dilution Biotechnology: -3.4%
    +244.3% Q4'25: +1,311.2% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.92× Q4'25: -0.65× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.61) × ERP
WACC = 75% × Ke + 25% × Kd (41.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.07
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2020
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana.
Revenue
83.0K
est: 40.0K (+107.5%)
35.00
est: 100.0K (-100.0%)
19.0K
est: 40.0K (-52.5%)
—
est: 30.0K (-100.0%)
30.0K
30.0K – 30.0K
+0.0% YoY
EBITDA
-8.44M
est: -24.0K (-35,045.8%)
-5.29M
est: -60.0K (-8,713.3%)
-5.25M
est: -8.0K (-65,470.7%)
-2.90M
est: -6.0K (-48,241.4%)
-6.0K
-6.0K – -6.0K
+0.0% YoY
EBIT
-8.60M
est: -24.0K (-35,725.0%)
-5.35M
est: -60.0K (-8,818.3%)
-5.25M
est: -8.0K (-65,470.7%)
-2.91M
est: -6.0K (-48,374.7%)
-6.0K
-6.0K – -6.0K
+0.0% YoY
Net Income
-10.75M
est: -10.91B (+99.9%)
-10.41M
est: -647.04M (+98.4%)
-5.72M
est: -20.01M (+71.4%)
-3.29M
est: -31.24M (+89.5%)
-40.72M
-40.72M – -40.72M
-30.3% YoY
SGA
2.60M
est: 418.89M (-99.4%)
1.82M
est: 1.05B (-99.8%)
2.98M
est: 3.36M (-11.3%)
1.54M
est: 2.52M (-38.8%)
2.52M
2.52M – 2.52M
+0.0% YoY
EPS
-670.72
est: -398.82 (-68.2%)
-32.16
est: -23.66 (-35.9%)
-0.21
est: -0.21 (+1.2%)
-0.03
est: -0.33 (+89.5%)
-0.43
-0.43 – -0.43
-30.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-26 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-25 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-19 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-18 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-15 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-14 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-08 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-05-07 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-05-06 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-05-04 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-30 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-29 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-28 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-27 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-24 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-23 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-22 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-21 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-17 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5
2026-04-16 C+ 2/5 4/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-6.67M
OE per share TTM
-0.15
Owner's Yield
-82.31%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
993.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
94.19M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Aram Mangasarian Chief Scientific Officer & Member of Management Board 287.4K —
Diede Mink van den Ouden Chief Executive Officer & Member of Management Board 24.8K male
Diede van den Ouden Chief Executive Officer & Director — male
Jarl Ulf Jungnelius Chief Medical Officer & Member of Management Board — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology